[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2196620T3 - Formulacion de liberacion prolongada que contiene venlafaxina. - Google Patents

Formulacion de liberacion prolongada que contiene venlafaxina.

Info

Publication number
ES2196620T3
ES2196620T3 ES98956487T ES98956487T ES2196620T3 ES 2196620 T3 ES2196620 T3 ES 2196620T3 ES 98956487 T ES98956487 T ES 98956487T ES 98956487 T ES98956487 T ES 98956487T ES 2196620 T3 ES2196620 T3 ES 2196620T3
Authority
ES
Spain
Prior art keywords
formulation
prolonged release
release containing
containing venlafaxine
venlafaxine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98956487T
Other languages
English (en)
Inventor
Deborah Marie Sherman
John Clifton Clark
John Ulrick Lamer
Stephen Andrew White
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25508423&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2196620(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth LLC filed Critical Wyeth LLC
Application granted granted Critical
Publication of ES2196620T3 publication Critical patent/ES2196620T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Núcleo de esferoide que comprende clorhidrato de venlafaxina y celulosa microcristalina, en el que núcleo de esferoide no contiene hidroxipropilmetilcelulosa.
ES98956487T 1997-11-05 1998-11-03 Formulacion de liberacion prolongada que contiene venlafaxina. Expired - Lifetime ES2196620T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96432897A 1997-11-05 1997-11-05

Publications (1)

Publication Number Publication Date
ES2196620T3 true ES2196620T3 (es) 2003-12-16

Family

ID=25508423

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98956487T Expired - Lifetime ES2196620T3 (es) 1997-11-05 1998-11-03 Formulacion de liberacion prolongada que contiene venlafaxina.

Country Status (39)

Country Link
EP (1) EP1028718B1 (es)
JP (1) JP2001521892A (es)
KR (1) KR20010031797A (es)
CN (1) CN1278165A (es)
AR (1) AR014012A1 (es)
AT (1) ATE237320T1 (es)
AU (1) AU747978B2 (es)
BG (1) BG104397A (es)
BR (1) BR9813179A (es)
CA (1) CA2305242A1 (es)
CL (1) CL2004001705A1 (es)
CO (1) CO5011060A1 (es)
CZ (1) CZ20001659A3 (es)
DE (1) DE69813602T2 (es)
DK (1) DK1028718T3 (es)
EA (1) EA200000487A1 (es)
EE (1) EE04577B1 (es)
ES (1) ES2196620T3 (es)
GE (1) GEP20043198B (es)
HK (1) HK1029056A1 (es)
HR (1) HRP20000213B1 (es)
HU (1) HU225238B1 (es)
ID (1) ID26317A (es)
IL (1) IL135457A0 (es)
MA (1) MA24691A1 (es)
NO (1) NO20002126L (es)
NZ (1) NZ504460A (es)
PA (1) PA8462501A1 (es)
PE (1) PE128699A1 (es)
PL (1) PL341141A1 (es)
PT (1) PT1028718E (es)
SK (1) SK6472000A3 (es)
SV (1) SV1998000131A (es)
TR (1) TR200001232T2 (es)
TW (1) TW555568B (es)
UA (1) UA77145C2 (es)
UY (2) UY25234A1 (es)
WO (1) WO1999022724A2 (es)
ZA (1) ZA9810081B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE397581T1 (de) * 1999-04-06 2008-06-15 Sepracor Inc O-desmethylvenlafaxin-succinat
ES2290027T3 (es) * 1999-05-20 2008-02-16 Elan Corporation, Plc Formulaciones multiparticuladas y de liberacion controlada de inhibidores selectivos de la recaptacion de serotonina.
IL146462A (en) 2001-11-13 2015-02-26 Lycored Bio Ltd Prolonged-release preparations containing as an active compound and analapaxin hydrochloride
US7030164B2 (en) * 2001-12-05 2006-04-18 Wyeth Crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
WO2003050074A1 (en) * 2001-12-13 2003-06-19 Cadila Healthcare Limited Manufacture of venlafaxine hydrochloride and crystalline polymorphs thereof
WO2003055475A1 (en) * 2002-01-03 2003-07-10 Lek Pharmaceutical And Chemical Company D.D. Controlled release pharmaceutical formulation containing venlafaxine
WO2003082262A2 (en) * 2002-03-28 2003-10-09 Synthon B.V. Compositions of venlafaxine base
AU2003219117A1 (en) * 2002-03-28 2003-10-13 Synthon B.V. Extended release venlafaxine formulations
US6696496B2 (en) 2002-03-28 2004-02-24 Synthon Bv Low water-soluble venlafaxine salts
WO2003082804A1 (en) 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
FR2845289B1 (fr) 2002-10-04 2004-12-03 Ethypharm Sa Spheroides, procede de preparation et compositions pharmaceutiques.
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
DE10350194B4 (de) * 2003-10-28 2005-11-10 Bioplanta Arzneimittel Gmbh Verwendung von Extrakten aus Opuntien zur Behandlung von depressiven Verstimmungen und Erkrankungen
TW200503670A (en) * 2003-03-28 2005-02-01 Sandoz Ag Venlafaxine compositions
ATE336988T1 (de) * 2003-07-30 2006-09-15 Pharmathen Sa Venlafaxine hydrochloridformulierungen mit verzögerter freisetzung
HUP0303382A2 (hu) * 2003-10-10 2005-08-29 EGIS Gyógyszergyár Rt. Venlafaxin-hidroklorid-tartalmú pelletek
EP1711169B1 (en) 2004-02-04 2007-05-09 Alembic Limited Extended release coated minitablets of venlafaxine hydrochloride
US7776358B2 (en) 2004-07-22 2010-08-17 Synthon Ip Inc. Extended release venlafaxine besylate tablets
JP5349290B2 (ja) * 2006-04-03 2013-11-20 オディディ，イサ 薬物送達組成物およびそれを含む医薬品、ならびにその製造方法
WO2007129329A2 (en) * 2006-05-08 2007-11-15 Jubilant Organosys Limited Extended release pharmaceutical formulation comprising venlafaxine hydrochloride
CN102772390B (zh) * 2012-08-16 2014-01-08 乐普药业股份有限公司 一种盐酸文拉法辛缓释胶囊及其制备方法
FR3080278B1 (fr) * 2018-04-11 2021-04-30 Ghs Patents Ltd Procede de fabrication d'un spheroide de cannabidiol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1561204A (en) * 1977-06-01 1980-02-13 Ici Ltd Sustained release pharmaceutical composition
US6440457B1 (en) * 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
PE57198A1 (es) * 1996-03-25 1998-10-10 American Home Prod Formula de liberacion prolongada
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.

Also Published As

Publication number Publication date
HRP20000213A2 (en) 2000-12-31
WO1999022724A3 (en) 1999-07-22
DE69813602D1 (de) 2003-05-22
CZ20001659A3 (cs) 2001-10-17
BR9813179A (pt) 2000-08-22
PE128699A1 (es) 2000-01-06
CO5011060A1 (es) 2001-02-28
UY25692A1 (es) 2000-03-31
EE200000212A (et) 2001-04-16
TR200001232T2 (tr) 2000-12-21
HU225238B1 (en) 2006-08-28
ATE237320T1 (de) 2003-05-15
MA24691A1 (fr) 1999-07-01
DE69813602T2 (de) 2003-11-06
CL2004001705A1 (es) 2005-06-03
DK1028718T3 (da) 2003-07-28
AR014012A1 (es) 2001-01-31
EA200000487A1 (ru) 2000-10-30
HRP20000213B1 (en) 2004-04-30
HUP0004287A2 (hu) 2002-04-29
NO20002126D0 (no) 2000-04-26
HUP0004287A3 (en) 2002-05-28
SV1998000131A (es) 1999-11-18
PT1028718E (pt) 2003-07-31
EP1028718B1 (en) 2003-04-16
GEP20043198B (en) 2004-03-25
SK6472000A3 (en) 2000-11-07
CN1278165A (zh) 2000-12-27
NZ504460A (en) 2003-01-31
EP1028718A2 (en) 2000-08-23
EE04577B1 (et) 2006-02-15
WO1999022724A2 (en) 1999-05-14
NO20002126L (no) 2000-05-04
ZA9810081B (en) 2000-05-04
AU747978B2 (en) 2002-05-30
JP2001521892A (ja) 2001-11-13
UY25234A1 (es) 2000-12-29
HK1029056A1 (en) 2001-03-23
BG104397A (en) 2001-02-28
KR20010031797A (ko) 2001-04-16
TW555568B (en) 2003-10-01
PA8462501A1 (es) 2000-05-24
PL341141A1 (en) 2001-03-26
ID26317A (id) 2000-12-14
AU1300399A (en) 1999-05-24
CA2305242A1 (en) 1999-05-14
IL135457A0 (en) 2001-05-20
UA77145C2 (en) 2006-11-15

Similar Documents

Publication Publication Date Title
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
ES2107235T3 (es) Tableta de liberacion prolongada, revestida con pelicula, de astemizol y pseudoefedrina.
MEP3608A (en) Modified-release tablet of bupropion hydrochloride
CO4750807A1 (es) Solucion de interferon
ATE268593T1 (de) Bupropionhydrochlorid enthaltende tabletten mit gesteuerter wirkstoffabgabe
TR199800077T1 (xx) Kontroll� ��z�len paroksetin terkipleri.
BR0011489A (pt) Composições formadoras de pelìcula compreendendo amidos modificados e iota-carragenano e processos para a fabricação de cápsulas macias usando as mesmas
BRPI0013439B8 (pt) composiÇço compreendendo tramadol e um fÁrmaco anticonvulsivante.
BR0006861A (pt) Processo de possibilitar que uma primeira rede doméstica de uma primeira arquitetura de software interaja com uma segunda rede doméstica de uma segunda arquitetura de software, sistema de processamento de informações, e, componente de software para uso em um sistema de ambiente doméstico
WO2004108067A3 (en) Programmed drug delivery system
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE59911249D1 (de) Substituierte 2-phenylbenzimidazole, deren herstellung und anwendung
BR0109943A (pt) Composições farmacêuticas
AR025247A1 (es) Composiciones de granulos de carotenos-xantofilos, estables
DE50202328D1 (de) Amidofunktionelle aminopolydiorganosiloxane
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
ES2191417T3 (es) Composicion desinfectante.
DK0984960T3 (da) N-triazol-2-indolcarboxamider og deres anvendelse som CCK-A-agonister
BRPI0012553B8 (pt) pastilha contendo cloridrato de ambroxol, seu processo de preparação e seu uso
MA26666A1 (fr) Antioxide, composition antiproliferee, y compris carnitine et carotenoide.
ATE235158T1 (de) Nicht klebende weiche süsswaren-zusammensetzung und methoden zu dessen herstellung
UY26556A1 (es) Compuestos calcilíticos
EA200000112A1 (ru) Новая композиция